Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G POSTS ONLY POINT-PLUS GAIN AS INDEX PLUNGES; ALL COMPONENTS OFF

Executive Summary

P&G POSTS ONLY POINT-PLUS GAIN AS INDEX PLUNGES; ALL COMPONENTS OFF Procter & Gamble (up 1-3/4 to 49-3/8) was the only stock on the 52-issue "F-D-C" Index to gain more than a point as pharmaceutical/diversified stocks followed the market downward. Thompson Medical (up 3/4 to 22), Revlon (up 5/8 to 37-3/4) and Sterling (up 1/8 to 25-1/4) were the only other Diversified stocks to gain ground. Hardest hit were 2-1/8 point decliners Bergen-B (to 22-1/8) and Americal Hospital Supply (to 33-1/4). Overall, only nine of 52 stocks on the index broke even with two stocks unchanged on the week. Losing ground among Pharmaceuticals were Searle (off 5-1/4 to 37-1/2), Schering (down 2 to 35-1/2), and 1-1/2 point losers Lilly (to 61-1/8) and Bolar (to 27-3/8). All other movement on the component was fractional. Chart omitted.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS006613

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel